GSK, Alcon And Otsuka Obtain Japanese Approval Recommendations
This article was originally published in PharmAsia News
Executive SummaryJapan's First Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare granted approval recommendations July 30 to GlaxoSmithKline's anti-allergic agent Xyzal (levocetirizine), Alcon Japan's Nevanac (nepafenac) for pain and swelling after cataract surgery, and Otsuka Pharmaceutical's Samsca (tolvaptan) for hypervolemic hyponatremia
You may also be interested in...
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.